Aeglea

AUSTIN, Texas, Feb. 3, 2021 /PRNewswire/ — Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the company’s chief financial officer, Charles N. York II, will be leaving the company effective February 12, […]